Non-viral delivery gene editing takes an important step forward for Angelman syndrome
A FAST-funded study unveils STEP-RNP, a non-viral gene editing platform showing improved motor, cognitive function in AS mice—an early but promising step toward treating Angelman syndrome.
FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies for Angelman syndrome
FAST launches MavriX Bio and CourageAS Bio, two new biotech companies advancing gene replacement and gene-editing therapies for Angelman syndrome under its AS²Bio accelerator.